Andrey.Volkov » 18 сен 2017, 16:22
Данные 2007г устарели .. Инозин включён в программу исследований терапии РС --помещено на этом самом сайте..
Ну и читайте источник если английский знаете
Objective: The objective of this study is to evaluate the safety and tolerability of inosine in patients with relapsing–remitting multiple sclerosis (RRMS). The secondary objectives are to assess the effects of inosine administration on serum urate (UA) levels, the progression of neurologic disability, the cumulative number of new, active lesions on magnetic resonance imaging (MRI), and changes in serum levels for markers of inflammation.
Design: Oral administration of inosine was used to raise serum levels of the natural peroxynitrite scavenger UA in 16 patients with RRMS during a 1-year randomized, double-blind trial.
Outcome measures: The endpoints studied were relapse rate, disability assessed by the Kurtzke Expanded Disability Status Scale (EDSS), MRI, and analysis of serum levels of nitrotyrosine, and oxidative and pro-inflammatory makers.
Results: Increased serum UA levels correlated with a significant decrease in the number of gadolinium-enhanced lesions and improved EDSS. A number of MRI intensity-based parameters were altered by inosine treatment, in certain cases correlating with changes in serum UA levels. In a patient with low serum UA and high lesion activity, raising UA levels by inosine treatment decreased serum nitrotyrosine while increasing the ratio of Th2 to Th1 cytokines in circulating cells. The only side-effect correlated with inosine treatment was kidney stone formation in 4/16 subjects.
Conclusions: These data suggest that the use of inosine to raise serum UA levels may have benefits for at least some MS patients. The effect of this treatment is likely to be a consequence of inactivation of peroxynitrite-dependent free radicals. Close monitoring of serum UA levels as well as other measures are required to avoid the potential development of kidney stones.
The Treatment of Multiple Sclerosis with Inosine) The Journal of Alternative and Complementary Medicine. June 2009, 15(6): 619-625
Clyde E. Markowitz, Sergei Spitsin, Vanessa Zimmerman, Dina Jacobs, Jayaram K. Udupa, D. Craig Hooper, и Hilary Koprowski
Последний раз редактировалось
Andrey.Volkov 18 сен 2017, 16:26, всего редактировалось 2 раз(а).
Numqu(am) hódi(e) induces út tibi cred(am) hóc argent(um) ignóto.
Lupus ést hom(o) homini, nón homo, quom quális sit non nóvit.